AssetMark Inc’s Accelerate Diagnostics AXDX Stock Holding History

AssetMark Inc’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-710	Closed	-$1.21K	–	2598
2024 Q3	$1.21K	Buy	+710	New	+$1.05K	﹤0.01%	1961

Other funds holding AXDX

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cannell & Spears New York $5.62B AUM 41.25% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BAM

Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

TWA

TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AssetMark Inc's AXDX Position: Q4 2024 in Review

AssetMark Inc sold out of Accelerate Diagnostics (AXDX) in Q4 2024, closing a stake of 710 shares — an estimated $1.21K sold.

AssetMark Inc first reported a position in AXDX in Q3 2024 and held it in 1 quarter. The position peaked at $1.21K in Q3 2024. 47 funds tracked by Wall St. Rank hold AXDX as of Q4 2024.

AssetMark Inc reported no remaining Accelerate Diagnostics position as of Q4 2024 after selling out during the quarter.
AssetMark Inc sold 710 Accelerate Diagnostics shares in Q4 2024, an estimated $1.21K.
AssetMark Inc first reported a position in Accelerate Diagnostics in Q3 2024 and held it in 1 quarter.
AssetMark Inc's Accelerate Diagnostics position peaked at $1.21K in Q3 2024.
47 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2024.

Based on AssetMark Inc's 13F filing for Q4 2024, filed 6 Feb 2025.